$1.35 2.3%
ACRS Stock Price vs. AI Score (Last 150 days)
Data gathered: July 16

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Aclaris Therapeutics

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States.


Aclaris Therapeutics
Price $1.35
Target Price Sign up
Volume 591,540
Market Cap $93M
Year Range $0.64 - $5.45
Dividend Yield 0%
Revenue per Employee $296,371
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '242.4M810,0001.6M-17M-13M-0.240
Q4 '2318M730,00017M-1.5M-4M-0.020
Q3 '239.3M850,0008.4M-29M-32M-0.410
Q2 '231.9M1M830,000-30M-32M-0.420
Q1 '232.5M810,0001.7M-28M-30M-0.400

Insider Transactions View All

Leonard Braden Michael filed to buy 13,447,969 shares at $1.1.
July 5 '24
Leonard Braden Michael filed to buy 13,324,952 shares at $1.2.
July 5 '24
Leonard Braden Michael filed to buy 13,181,664 shares at $1.1.
July 5 '24
Leonard Braden Michael filed to buy 13,095,572 shares at $1.1.
July 1 '24
Leonard Braden Michael filed to buy 12,988,134 shares at $1.1.
July 1 '24

What is the Market Cap of Aclaris Therapeutics?

The Market Cap of Aclaris Therapeutics is $93M.

How Many People Work at Aclaris Therapeutics?

As of our latest update, Aclaris Therapeutics employed approximately 105 people worldwide. However, it's important to note that Aclaris Therapeutics' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Aclaris Therapeutics' revenue per employee?

$296,371. To calculate Aclaris Therapeutics' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Aclaris Therapeutics?

Currently, the price of one share of Aclaris Therapeutics stock is $1.35.

How can I analyze the ACRS stock price chart for investment decisions?

The ACRS stock price chart above provides a comprehensive visual representation of Aclaris Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Aclaris Therapeutics shares. Our platform offers an up-to-date ACRS stock price chart, along with technical data analysis and alternative data insights.

Does ACRS offer dividends to its shareholders?

As of our latest update, Aclaris Therapeutics (ACRS) does not offer dividends to its shareholders. Investors interested in Aclaris Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Aclaris Therapeutics?

Some of the similar stocks of Aclaris Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.